Login to Your Account



Pharma: Other news to note


Thursday, January 23, 2014
Eisai Inc., of Woodcliff Lake, N.J., said the European Commission granted orphan drug status to amituximab, discovered and developed by Morphotek Inc., of Exton, Pa., a wholly owned subsidiary of Eisai, for malignant mesothelioma.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription